Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:21:15 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:PSTV - PLUS THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PSTV - Q0.51.65·1.950.11.6914-0.0986-5.57.210401.735  1.79  1.68725.0975  0.9694Apr 18Apr 0915 min RT 2¢

Recent Trades - Last 10 of 40
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-09 07:00U:PSTVNews ReleaseNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team
2024-03-27 08:00U:PSTVNews ReleasePlus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
2024-03-25 08:00U:PSTVNews ReleasePlus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
2024-03-11 07:00U:PSTVNews ReleasePlus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
2024-03-05 16:05U:PSTVNews ReleasePlus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
2024-02-27 08:00U:PSTVNews ReleasePlus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
2023-12-18 07:00U:PSTVNews ReleasePlus Updates Financial and Cash Guidance for 2024
2023-12-12 08:00U:PSTVNews ReleasePlus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
2023-11-29 08:00U:PSTVNews ReleasePlus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe
2023-11-20 07:00U:PSTVNews ReleasePlus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
2023-11-15 07:00U:PSTVNews ReleasePlus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
2023-11-13 09:31U:PSTVNews ReleaseThinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?
2023-11-03 07:00U:PSTVNews ReleasePlus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
2023-10-31 16:10U:PSTVNews ReleasePlus Therapeutics Announces Share Repurchase Program
2023-10-31 16:05U:PSTVNews ReleasePlus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
2023-10-25 09:22U:PSTVNews ReleasePlus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
2023-10-23 16:05U:PSTVNews ReleasePlus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023
2023-10-10 07:00U:PSTVNews ReleasePlus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium ( ‚ ¹ ¢  ¸ ¢  ¶Re) Obisbemeda in Leptomeningeal Metastases
2023-10-09 07:00U:PSTVNews ReleasePlus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October